Maximus (Flurbiprofen oromucosal preparations) is commonly used for symptomatic relief in conditions marked by acute and localized discomfort in the throat and mouth. The medication is used in contexts where additional symptomatic support is needed, aligning with the indication for the short-term symptomatic relief of acute sore throat.

The medication is generally applied in addressing symptom clusters associated with inflammatory or irritative states. Its core therapeutic domains include easing acute pain and soreness, managing associated swelling and irritation, and addressing the functional strain of painful swallowing (dysphagia). It is used in situations involving certain distressing symptoms that frequently accompany conditions like pharyngitis and tonsillitis.

“It is commonly used when short-term symptomatic assistance is needed, relevant in contexts marked by increased discomfort.”

Quick Fact Block

Quick Fact: Relief for Acute Discomfort	Description
Primary Symptom	Acute pain and soreness localized to the throat.
Functional Benefit	Supports easing the pain associated with difficulty swallowing.
Context of Use	Conditions characterized by periods of heightened symptoms, like pharyngitis.

Regulatory References

1. European Commission therapeutic overview

Eligibility and Contraindications for Maximus

Maximus (Flurbiprofen oromucosal preparations) is subject to strict eligibility rules based on official regulatory labeling. Use is generally limited to specific age groups and is prohibited for populations with certain pre-existing conditions.

---

Age-Related Eligibility	Official Regulatory Status
Lozenges	Allowed for adults and adolescents 12 years or older; not indicated for younger children.
Oral Spray	Contraindicated for children and adolescents below 18 years (in specific markets).
Geriatric Use	Use is allowed, but caution is required due to increased risk of serious adverse reactions, especially GI bleeding.

---

Absolute Contraindications (Must Not Be Used)

• Hypersensitivity: Patients with known allergy to Flurbiprofen or any ingredients, or previous allergic reactions (e.g., asthma, angioedema) to Aspirin or other NSAIDs.
• Organ Failure: Patients with severe heart failure, severe renal failure, or severe hepatic failure.
• Gastrointestinal (GI) History: History of active or recurrent peptic ulcer/haemorrhage (two or more episodes) or severe colitis related to prior NSAID use.
• Pregnancy: Women in the last/third trimester of pregnancy.

---

Use Requires Caution or is Restricted

Use requires caution in patients with a history of hypertension, heart failure, or bronchial asthma. Individuals with mild-to-moderate renal or hepatic impairment may use the medicine without dose adjustment, but severe impairment is a contraindication. The medicine is not recommended for women who are actively attempting to conceive.

Interactions with other medicines and products

Official regulatory information for Maximus (Flurbiprofen) outlines necessary restrictions and cautions regarding co-administration with several medicinal products and substances.

Interaction Classifications

Classification Type	Official Regulatory Description
Interaction Severity Classification	Contraindicated (e.g., severe renal/hepatic insufficiency, third trimester of pregnancy, CABG procedure); Avoid Co-administration (e.g., other NSAIDs); Use with Caution/Monitor (e.g., Warfarin, Lithium, Antihypertensives).
Regulatory Basis	Based on requirements from official regulatory documents, including EMA SmPC and FDA Prescribing Information.
Interaction-Context Constraints	Concurrent use with alcohol may increase the risk of adverse gastrointestinal reactions, including bleeding.

---

Official Interaction Statements

• Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Acetylsalicylic Acid (Aspirin), including low doses, is not generally recommended due to an amplified risk of adverse effects.
• The combination with anticoagulants (e.g., Warfarin) and anti-platelet agents increases the risk of bleeding due to pharmacodynamic enhancement of their effects.
• Flurbiprofen may reduce the antihypertensive effect of ACE-inhibitors, ARBs, and diuretics.
• The drug may increase the plasma concentrations of Lithium and Methotrexate due to reduced clearance, potentially elevating their systemic exposure.
• A mandatory separation rule exists: the product should not be used for 8–12 days after Mifepristone administration as NSAIDs can reduce its effect.
• Caution is necessary in elderly or volume-depleted patients taking ACE-inhibitors or ARBs, due to a heightened risk of renal function deterioration.

How Maximus Works

Maximus, containing the active substance Flurbiprofen, operates through a defined pharmacodynamic mechanism centered on the inhibition of the Cyclooxygenase ( COX) enzyme system. Flurbiprofen functions as a non-selective competitive inhibitor of both the constitutive enzyme COX-1 and the inducible enzyme COX-2.

By occupying the active site of these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins and other prostanoids. This molecular blockade curtails the local formation of these critical inflammatory and nociceptive mediators. This reduction in prostaglandin levels initiates a physiological cascade that shapes the drug’s pharmacodynamic signature. The reduction decreases the chemical sensitization of peripheral nociceptors (pain receptors) and diminishes the prostaglandin-induced increases in capillary permeability and vasodilation. This simultaneous modulation of nociceptor signaling and vascular function defines the drug's activity profile.

Maximus is a pharmaceutical preparation containing Flurbiprofen, designated for local, non-systemic use. The medicine is administered via the oromucosal route, meaning the dose is intended to act directly on the mucous membranes of the mouth and throat.

The standard adult and adolescent regimen involves a single dose of 8.75 mg Flurbiprofen per unit, taken as needed for symptoms. Frequency is typically limited to one unit every 3 to 6 hours. Total intake is limited to a maximum of 5 units in any 24-hour period. Administration requires the lozenge to be dissolved slowly in the mouth and moved around while sucking to ensure uniform mucosal contact and minimize local irritation.

---

Administration Guidelines Summary

Instruction Domain	Guideline Specifications
Route of Administration	Oromucosal (local delivery to mouth/throat lining).
Dosing Schedule	Single dose of 8.75 mg Flurbiprofen per unit.
Frequency	One unit every 3 to 6 hours, as required.
Maximum 24h Dose	5 units.

The usage protocol is based on the shortest duration necessary for symptom management. The maximum limit for a single course of use is three days. Furthermore, the administration guidelines establish an age constraint: the product is not indicated for use in children under 12 years of age. These parameters facilitate the standardized use of the medicine across patient applications.

Research Evidence / Overview of Studies for Maximus

Evidence for Use in Acute Sore Throat Symptom Management

The clinical evaluation for Maximus primarily examines its use in short-term symptom management in conditions associated with acute sore throat. The core evidence for this purpose comes from multiple Randomized Controlled Trials (RCTs) and Meta-analyses, which are study types where the treatment is compared against an inactive control (a placebo) to evaluate differences in the patient-reported experiences compared to a control.

Research has explored how symptoms change over time in adults experiencing episodes where symptoms become more noticeable, such as acute pharyngitis. The studies monitored patient-reported outcomes describing perceived discomfort. These primary measurements included changes in the intensity of sore throat pain and difficulty swallowing. Studies monitored patient-reported changes in pain and swallowing difficulty, reporting patterns that differed from those observed in the groups receiving the placebo over the defined time intervals.

Research Context: Symptom Management Alongside Antibiotic Therapy

Research has also examined the use of Maximus in a specific scenario: when patients with confirmed bacterial sore throat are also receiving standard antibiotic therapy. This evidence is primarily based on secondary analyses of data collected within the main RCTs, rather than new, dedicated trials. These studies explored how symptoms evolved in the observed populations that were receiving both the symptomatic treatment and an antibiotic. The analysis examined measurements of pain and swallowing difficulty during the initial phase of antibiotic co-administration.

Long-Term Studies and Follow-Up Duration

All available evidence for Maximus focuses on acute relief. The initial efficacy studies were conducted over very short timeframes. Single-dose observations were studied for a few hours, while multi-dose trials typically monitored responses over defined time intervals, usually for a period of up to three days. Because the research focus is on short-term, acute symptom patterns, research exploring sustained benefits or long-term outcomes is not the focus of the current evidence landscape. Consequently, long-term effects are not fully established.

What Research Gaps and Uncertainties Remain

The research record highlights several limitations and areas where data remain incomplete. The primary limitation is the follow-up durations were limited to the acute symptomatic phase, meaning the research provides limited information for outcomes during chronic or recurring conditions. Comparative evidence is lacking against a broad array of other sore throat remedies. Data for certain groups, such as children under 12 years of age, also remain insufficient in the core research record.

Key Studies & References

1. Flurbiprofen Geiser 8,75 mg oromucosal spray, solution and associated names - Annex I-II-III (European Commission Regulatory Document)
2. A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
3. NCT01049334 | A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis (Clinical Trial Registry)

Common questions about Maximus (FAQ)

---

Q: How quickly can I expect Maximus to start working after I begin taking it?

Studies indicate that Flurbiprofen 8.75 mg lozenges may provide symptom relief relatively quickly. Relief of sore throat pain has been observed in clinical research as early as 12 to 26 minutes after the first dose. The effects of a single unit are generally expected to last for a period of up to three to four hours.

---

Q: Are there any specific foods or drinks that should be avoided while using Maximus?

Official product information describes that the use of alcohol is generally not recommended during treatment. This restriction is advised because concurrent use with alcohol may increase the risk of adverse gastrointestinal (stomach and intestine) reactions, including the risk of bleeding.

---

Q: Is a headache a normal side effect when first starting Maximus?

Headache is classified as a common side effect in official regulatory documents. This classification means that up to 1 in 10 people who use the medicine may experience it. The available official information does not specifically indicate whether this effect is more likely to occur only when first starting treatment.

---

Q: Has Maximus been studied in pediatric patients?

The official regulatory indication is for adults and adolescents 12 years of age and older. The product is not indicated for children younger than 12 years. This is because official documents note that the clinical experience and safety data available for use in children below this age are considered insufficient.

---

Q: Does taking certain antibiotics affect how Maximus works?

Research has examined the use of Flurbiprofen lozenges when co-administered alongside antibiotics for a bacterial sore throat. These studies indicated that the effectiveness of the lozenge in relieving sore throat pain was not reduced by the concurrent use of antibiotics.

---

Q: Is Maximus a controlled substance or does it have a high potential for misuse?

The active ingredient, Flurbiprofen, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory documents do not classify this medicine as a controlled substance. There is no indication in the official labeling that it has a high potential for dependence or misuse.

---

Q: Does Maximus affect my ability to drive or operate machinery?

The official product label notes that certain side effects, such as dizziness and visual disturbances, are possible while using this medicine. Regulatory information notes that if these effects occur, activities requiring alertness, such as driving or operating machinery, may be affected.

---

Q: Do I need to stop taking Maximus suddenly, or should I reduce the amount gradually?

Maximus is intended for short-term use only, with a maximum duration of three days. Official guidance documents indicate that treatment is to be discontinued immediately if an individual notices the first signs of a skin rash, mucosal lesions, or signs of hypersensitivity.

---

Q: Is it true that Maximus can cause sleepiness?

Yes, drowsiness (feeling sleepy) is listed as an uncommon side effect, potentially affecting up to 1 in 100 people. Other related effects such as dizziness are classified as common. This information is based on the frequency categories established in official regulatory documents.

---

Q: What should I do if I think I am having a side effect from Maximus?

Regulatory guidance specifies that if signs of a serious adverse reaction occur, particularly unusual abdominal symptoms (especially bleeding) or an allergic reaction, the medicine is to be stopped immediately. These instructions reflect the precautions outlined for managing potential serious adverse events.

---

Q: Is there a link between using Maximus and changes in mood?

While general mood changes are not explicitly listed, the NSAID class of medicines has been associated with certain psychiatric effects in studies of other forms of the drug. These documented effects include insomnia (difficulty sleeping), nervousness, and in rare cases, anxiety or depression.

---

Q: Can I take Maximus if I have diabetes?

Diabetes mellitus is not listed as an absolute prohibition (contraindication) for using the medicine. However, official regulatory information states that patients with risk factors for cardiovascular disease, which includes diabetes, are a population where caution is warranted.

---

Q: Is there a risk of becoming dependent on Maximus?

Flurbiprofen is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory documents do not classify this medicine as a controlled substance and do not indicate a risk of dependence or addiction for this medicine.

---

Q: What happens when people stop using Maximus?

Maximus is only indicated for the acute, short-term relief of symptoms. Treatment should be withdrawn (stopped) if symptoms worsen, new symptoms appear, or if mouth irritation occurs. The medicine is not associated with effects that require a specific tapering schedule after short-term use.

---

Q: Is it normal to feel a change in appetite after starting Maximus?

Some official documents for the Flurbiprofen class of medicines have listed loss of appetite, which is often related to other reported gastrointestinal effects. However, research for the lozenge form noted that relief of symptoms resulted in an improvement in loss of appetite when compared to patients’ symptoms before treatment.

Official Storage and Disposal Profile

Official regulatory documents detail the precise conditions required to maintain the stability and efficacy of Maximus. This includes mandatory labeled storage temperature requirements, such as refrigeration (2 C to 8 C) or storage not above 30 C, as stated on the product label. The medicine must be kept in its original container to protect it from light and moisture.

Following reconstitution or initial opening, a documented in-use stability period applies, after which any unused portion must be discarded. To prevent accidental exposure, regulatory guidance mandates that the medicine be stored out of the sight and reach of children.

Disposal instructions require the return of unused or expired product to drug take-back programs. If this option is unavailable, the medicine must be rendered unappealing by mixing it with materials like used coffee grounds or dirt, sealed in a bag, and placed in the household trash. It must not be flushed down the toilet unless explicitly authorized by regulatory guidance.